“We are honoured that Neuronetics chose us as a supplier for its system and extremely pleased to be selected for this prestigious award. Over the past four years, Molex has worked with Neuronetics to improve and perfect the SenStar Treatment Link assembly for patient comfort and effectiveness,” said Justin Spitzer, business development manager, Molex Incorporated. “This has culminated in the NeuroStar TMS Therapy system being recently cleared by the U.S. Food and Drug Administration for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication.”
The NeuroStar TMS Therapy system is an electromagnetic medical device for the treatment of major depressive disorder. It operates by applying a focused, pulsed magnetic field that inductively stimulates cortical neurons associated with depression.
The patented SenStar, supplied by Molex, is an integrated flexible switch and circuit assembly which includes an x-y position sensing, non-tactile membrane switch and a flexible circuit. The switch portion provides feedback for proper positioning of the Neurostar Treatment Coil while the flexible circuit reduces scalp sensation during treatment.